MPM Bioimpact
MPM BioImpact is building companies to transform patient outcomes.
In the firm's own words, from its website.
28 additional team members, 24 additional co-investors and affiliates, 61 additional investments, funds and LPs, 69 events, 1 verified contact (1 firm phone)
Every relationship, signal and contact on this record, with the source on each.
Includes 3 days of DFX Intelligence. Then $199/month unless canceled.
What matters now
- 1 companynew in 12 months
1 new company in the last 12 months.
A firm writing cheques this quarter is one a founder can pitch now.
- 1 companyportfolio raising
One portfolio company has new financing on record in 6 months without this firm named on the round; the latest on 22 Jul 2026 ($33.7M sold on Form D).
A portfolio company raising again is a follow-on decision for the firm and a co-investment opening for others.
- 4 dealswith NEA: New Enterprise Associates
Invests most often alongside NEA: New Enterprise Associates (4 shared deals) and Pitango VC (3 shared deals). 13 of the 26 most frequent co-investors were first seen with it on record in the last 12 months.
pair last observed on record 20 Jan 2017, not a deal date · The firms it syndicates with are the likeliest to see the same deals and to fill out its rounds.
Measuredshared rounds and portfolio companies on recordFor Founders building a round, co-investorsCo-investors →
People to know
View all people- Entrepreneur PartnerWhy: Partner: part of the investment decisionNo route on file yet
- Managing DirectorWhy: Managing directorNo route on file yet
- MemberWhy: Named with investment responsibilityNo route on file yet
Relationship network
121 connected entities27 observed rounds11 repeat counterparties1 dated round shown here, 2025
From financing rounds and every investor named in them, Form ADV and Form D filings, the firm's funds and team, and disclosed LP commitments in the venture capital graph. A round's amount is the size of the round, not money that moved between two investors.
Some relationships on this record are counted rather than named here. They open with the full profile.
Click any name or line for the rounds and sources behind it. Line weight is rounds together; dashed lines are inferred.
- Sponsor
- Company
- Fund or vehicle
- Person
›How strength and recency are read
Co-investors are read from the rounds: three or more shared rounds is a strong observed relationship, two a repeat co-investor, one a single round. Funds and people are structural. Nothing is scored that a reader cannot check.
Darker lines were active in the last 24 months or are current; lighter lines are older or undated.
How am I connected?
Name your firm, a company or a person, and DFX finds the published routes to MPM Bioimpact: a shared portfolio company or board, a prior employer, a co-investor, a shared LP or service provider. Every step is a filed or published record with its source; none is a guess about who knows whom.
See how you connect to MPM Bioimpact
Includes 3 days of DFX Intelligence. Then $199/month unless canceled.
Investing
32 companies on record, 1 new in 12 months
Investments on record
What these amounts mean“This investor” is the amount disclosed for this investor alone; it is unknown unless a source said it. The round size is the whole round.Acquired, Public, Exited and Active are what the firm’s own portfolio card says, read on the date shown when you hover the chip; they are not deal dates. A company with no chip is one whose card states no outcome: DFX does not assume it is active.| Company | Round | Role | Partner | Round size | This investor | Date | Source |
|---|---|---|---|---|---|---|---|
| Aktis Oncology, Inc. | portfolio listing | unknown | unknown | unknown | unknown | Sep 30, 2026 | Fact Firm website |
| Ashibio | portfolio listing | unknown | unknown | unknown | unknown | Sep 30, 2026 | Fact Firm website |
| AstronauTx | portfolio listing | unknown | unknown | unknown | unknown | Sep 30, 2026 | Fact Firm website |
Stated thesis versus observed behaviour
- Sectors
- healthcare, biotech
- Stages
- series a, early
- Geography
- boston, global
- Check size
- not stated; DFX does not estimate checks from round sizes
Team
20 current, 26 departed
Decision makers
- Andrew M. Scharenberg · Entrepreneur PartnerWhy this person: Partner: part of the investment decision; Named with investment responsibility
- Todd Foley · Managing DirectorWhy this person: Managing director; Named with investment responsibility
Ranked by the role the firm or its filing states, a route on file and deals led. Every reason is read from the record, never inferred. Routes are published by the person or the firm (their bio, the team page or a filing) and are revealed on a plan; data bought from a provider is never shown, and a route printed at a firm the person has since left is held back.
Investment team
How the team is orderedPartners who lead rounds first (rounds led, then deals attributed, then seniority), then the rest of the investment team, then investor relations, finance and operations. A person named by two sources under two spellings is shown once.- Managing Director · 10 deals attributed
- Member · 7 deals attributed
- Entrepreneur Partner · 1 deal attributed
11 departed (kept with end dates)
- Bard Geesaman · Managing Director · Nov 1, 2015 to Mar 28, 2019 Inference
- Edward Martin Hurwitz · Managing Director · Nov 1, 2015 to Mar 30, 2023 Inference
- James Paul Scopa · Managing Director · Nov 1, 2015 to Mar 30, 2018 Inference
Contacts
1 firm phone on record, each with its source. Values open with the complete profile.
Funds and LPs
21 vehicles, 0 LPs disclosed
Funds and vehicles
What these amounts meanGAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.| Vehicle | Type | Vintage | Lifecycle | Reported GAV | Owners | Form D sold | Latest Form D |
|---|---|---|---|---|---|---|---|
| UBS Oncology Impact Fund L.P. | SPV or co-invest vehicle · ADV: Other Private Fund | 2023 adv first reported | Active deployment | $570M Apr 28, 2026 | 660 | unknown | unknown |
| MPM Bioventures 2022, L.P. | Fund | 2022 name year | Active deployment | $351M Apr 28, 2026 | 47 | $351M | Jun 1, 2023 |
| Oncology Impact Fund 2, L.P. | Fund · ADV: Other Private Fund | 2020 form d first sale | Mature | $1.0B Apr 28, 2026 | 33 | $327M | Nov 22, 2021 |
Limited partners
Known LPs and allocators
What these amounts and dates areEach commitment is counted once across the pension tape and the allocator graph. A commitment date prints only when the source printed one; otherwise the row carries the report date. A foundation’s 990-PF line is a holding at fair value, never a commitment. Rows without a fund on the venture graph are commitments to this manager.| Allocator | Type | Fund | Amount | Date | Source |
|---|---|---|---|---|---|
| Hawaii Employees' Retirement System | STATE RETIREMENT SYSTEM | MPM Bioventures V, L.P. | $4.0M committed | reported as of Dec 31, 2025 | Fact Pension disclosure |
Relationships across DFX
26 co-investors · on 3 other DFX graphs
Co-investors
- 2017-01-204 shared deals · strong
- 2014-07-073 shared deals · recurring
- 2025-12-012 shared deals · recurring
Across DFX and the capital chainon 3 other DFX graphs · 1 capital path ShowHide
- The same institution is held on Private Equity, RIA and Wealth, Private Credit, matched by identifier. See which records
MPM Bioimpact is the same institution as 3 records in Private Equity, RIA and Wealth and Private Credit.
DFX found 3 relationships across 3 datasets
Which record it is in each graph, what it is called there, and how the two were matched.
Includes 3 days of DFX Intelligence. Then $199/month unless canceled.
Checking your plan…
MPM Bioimpact sits on 1 traced path of capital across the graphs.
DFX traced 1 path of capital through this record
Every record on each path, what it committed or lent, and as of when.
Includes 3 days of DFX Intelligence. Then $199/month unless canceled.
Derived from allocator disclosures, BDC schedules and SEC filings; confidence is the weakest hop.
Checking your plan…
Evidence and history
74 dated events, 85 observations from 4 sources
Timeline
- Apr 28, 2026NEW Technologies and Virology Fund, L.P. first reported on Form ADV by MPM Bioimpact (Other Private Fund), GAV $140,218,597
- Mar 28, 2024MPM Sunstates Fund, L.P. no longer reported on Form ADV by MPM Bioimpact
- Mar 28, 2024MPM Asset Management Investors Sunstates Fund LLC no longer reported on Form ADV by MPM Bioimpact
- Jan 1, 2024Robert Samuel Risoleo joined Schedule A of MPM Bioimpact as General Counsel
- Mar 30, 2023Oncology Impact Fund 2, L.P. first reported on Form ADV by MPM Asset Management LLC (Other Private Fund), GAV $828,188,146
Identity and regulatory footprint
Address, phone, Form ADV filing and ownersForm ADV filed Apr 28, 2026 · 14 private fundsShowHide
- Headquarters
- Boston, MAadviserinfo.sec.gov
- Office address
- unknownadviserinfo.sec.gov
- Business phone
- unknownadviserinfo.sec.gov
- Website
- MPMBioImpact.COM
- SEC adviser type
- Registered investment adviseradviserinfo.sec.gov
- SEC exemption claimed
- unknown
- Latest Form ADV
- Apr 28, 2026
- Private funds reported
- 14 (8 venture capital funds)adviserinfo.sec.gov
- Private fund gross assets, adviser total
- $3.5Badviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
- Regulatory AUM
- $3.6Bthe adviser's RAUM, a regulatory measure, never a fund size
- Employees
- 50
- Owners on Schedule A
- Ansbert K. Gadicke 2015 Irrevocable Trust II (Member), owns 25% to 50%; Gadicke 2012 Irrevocable Trust (Member), owns 25% to 50%; MPM Founders LLC (Member), owns 75% or more
Classification history
Classification history
Every classification this record has carried3 on recordShowHide
- Sep 23, 2026Institutional venture firm (probable, 80%)Venture manager, reported GAV $2.9B across 21 vehicles
- Sep 15, 2026Institutional venture firm (probable, 80%)Venture manager, reported GAV $3.0B across 20 vehicles
- Sep 12, 2026Institutional venture firm (probable, 80%)Venture manager, reported GAV $3.0B across 17 vehicles
Evidence
Every observation behind this profile, with its source, date and class
| Fact | Value | Effective | Class | Source |
|---|---|---|---|---|
| Why admitted | VC funds reported | Apr 28, 2026 | Fact | Form ADV |
| SEC adviser type | Registered investment adviser | Apr 28, 2026 | Fact | Form ADV |
| SEC adviser type | Registered investment adviser | Apr 28, 2026 | Fact | Form ADV |
| SEC adviser type | Registered investment adviser | Jun 26, 2024 | Fact | Form ADV |
| First Form ADV filing | 2012-03-28 | Apr 28, 2026 | Fact | Form ADV |
| First Form ADV filing | 2012-03-28 | Jun 26, 2024 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-09-30 | Oct 1, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-09-29 | Sep 30, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-09-25 | Sep 26, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-09-23 | Sep 24, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-09-21 | Sep 23, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1+panel:2026-09-22 | Sep 23, 2026 | Fact | Form ADV |
| Adv history loaded | adv-hist-1 | Sep 12, 2026 | Fact | Form ADV |
| Latest Form ADV filing | 2026-04-28 | Apr 28, 2026 | Fact | Form ADV |
| Latest Form ADV filing | 2026-04-28 | Apr 28, 2026 | Fact | Form ADV |
| Latest Form ADV filing | 2024-06-26 | Jun 26, 2024 | Fact | Form ADV |
| SEC status | Approved | Apr 28, 2026 | Fact | Form ADV |
| SEC status effective | 2016-01-04 | Apr 28, 2026 | Fact | Form ADV |
| Venture share of reported funds | 1 | Apr 28, 2026 | Fact | Form ADV |
| Venture share of reported funds | 1 | Jun 26, 2024 | Fact | Form ADV |
| Business phone | Apr 28, 2026 | Fact | Form ADV | |
| Business phone | Jun 26, 2024 | Fact | Form ADV | |
| Description | Sep 30, 2026 | Fact | ||
| Description | Sep 16, 2026 | Fact | ||
| Description | Sep 14, 2026 | Fact | ||
| Employees | 50 | Apr 28, 2026 | Fact | Form ADV |
| Employees | 50 | Jun 26, 2024 | Fact | Form ADV |
| Headquarters | Boston, MA | Apr 28, 2026 | Fact | Form ADV |
| Headquarters | Boston, MA | Jun 26, 2024 | Fact | Form ADV |
| Office address | Apr 28, 2026 | Fact | Form ADV | |
| Office address | Jun 26, 2024 | Fact | Form ADV | |
| Legal form | Limited Liability Company | Apr 28, 2026 | Fact | Form ADV |
| Other funds reported | 3 | Apr 28, 2026 | Fact | Form ADV |
| Portfolio page | Sep 30, 2026 | Fact | ||
| Portfolio page | Sep 16, 2026 | Fact | ||
| Portfolio page | Sep 14, 2026 | Fact | ||
| Private funds reported | 14 | Apr 28, 2026 | Fact | Form ADV |
| Private funds reported | 14 | Apr 28, 2026 | Fact | Form ADV |
| Private funds reported | 21 | Jun 26, 2024 | Fact | Form ADV |
| Private fund gross assets (reported) | $3.5B | Apr 28, 2026 | Fact | Form ADV |
| Private fund gross assets (reported) | $3.5B | Apr 28, 2026 | Fact | Form ADV |
| Private fund gross assets (reported) | $3.3B | Jun 26, 2024 | Fact | Form ADV |
| Regulatory AUM (adviser, not fund size) | $3.6B | Apr 28, 2026 | Fact | Form ADV |
| Regulatory AUM (adviser, not fund size) | $3.3B | Jun 26, 2024 | Fact | Form ADV |
| Schedule a diff | sadiff-1 | Sep 29, 2026 | Fact | Form ADV |
| Stated geography | Boston, global “geography words on the home page” | Sep 30, 2026 | Fact | |
| Stated geography | Boston, global “geography words on the home page” | Sep 16, 2026 | Fact | |
| Stated geography | Boston, global “geography words on the home page” | Sep 14, 2026 | Fact | |
| Stated sectors | Healthcare, biotech “sector words on the home page” | Sep 30, 2026 | Fact | |
| Stated sectors | Healthcare, biotech “sector words on the home page” | Sep 16, 2026 | Fact | |
| Stated sectors | Healthcare, biotech “sector words on the home page” | Sep 14, 2026 | Fact | |
| Stated stages | Series a, early “stage words on the home page” | Sep 30, 2026 | Fact | |
| Stated stages | Series a, early “stage words on the home page” | Sep 16, 2026 | Fact | |
| Stated stages | Series a, early “stage words on the home page” | Sep 14, 2026 | Fact | |
| Team page | Sep 30, 2026 | Fact | ||
| Team page | Sep 16, 2026 | Fact | ||
| Team page | Sep 14, 2026 | Fact | ||
| Venture funds reported | 8 | Apr 28, 2026 | Fact | Form ADV |
| Venture funds reported | 8 | Apr 28, 2026 | Fact | Form ADV |
| Venture funds reported | 17 | Jun 26, 2024 | Fact | Form ADV |
| Website | Sep 12, 2026 | Fact | Form ADV | |
| Website | Jun 26, 2024 | Fact | Form ADV | |
| Site title | Sep 30, 2026 | Fact | ||
| Site title | Sep 16, 2026 | Fact | ||
| Site title | Sep 14, 2026 | Fact |
How this is scored
Scores, classification basis and filing advisersInstitutional venture firm, probableShowHide
Venture manager, reported GAV $2.9B across 21 vehicles
- importance
- gav: 0.75 · funds: 1 · people: 0.36 · investments: 0.61 · co investors: 0.57
- active deployment
- investments 12m: 0.25 · fund raising 18m: 0 · people joined 12m: 0 · vintage within 3y: 1 · latest investment at: 2026-07-30
- emerging manager
- fund count: 36 · reported gav: $2.9B · first adv filing: 2012-03-28 · years since first filing: 14.5
Fits, record history and connections
scored matches for this investor, every identity change, every edge
Fits
- score 38.7confidence 100%Why: sector fit; geography fit; activity; analogousWatch: adjacent portfolio
- score 38.7confidence 100%Why: sector fit; geography fit; activity; analogousWatch: adjacent portfolio
- score 34.7confidence 100%Why: sector fit; geography fit; activity; analogousWatch: adjacent portfolio
+1 more scored match
Includes 3 days of DFX Intelligence. Then $199/month unless canceled.
Scored by DFX match engines from the record's observed portfolio, stage, geography and recent activity. A fit is a reason to look, not a mandate; the blockers say what the model could not confirm. Names and the evidence sentences show with the names on this page.
Record history
- Adviser's first ADV filing2012-03-28source on record
The ledger records every merge, rename and reclassification this record went through and the dated filings observed on it, so the identity on this page can be traced to the records it was built from. The ledger's own sentences name other records, so they show with the names.